Company & Sponsor Intelligence
Neurotrope Bioscience, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed2
Countries1
Therapeutic footprint
alzheimers
Indexed studies
NCT04538066Bryostatin Treatment of Moderately Severe Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT02221947Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease
alzheimers · United StatesPHASE1, PHASE2
alzheimers · United StatesPHASE1, PHASE2
NCT02431468A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →